Software improves on breast density assessment algorithm with artificial intelligence.
Volpara Health announced Friday it has received 510(k) clearance from the U.S. Food & Drug Administration for the latest version of Volpara Imaging Software.
This version – VIS 3.2 – incorporates learnings from artificial intelligence to augment the robustness of the breast density assessment algorithm. In addition, this clearance approves VIS 3.2 for use on other mammography machines, including those from Giotto and Siemens.
The new version offers improved imaging processing security through the Open Virtual Appliance architecture, and it also makes it easier for Volpara to monitor, services, and update software, company officials said.
“These new innovations improve the overall security, scalability, robustness, and breadth of our breast health offering,” said Ralph Highnam, Ph.D., Volpara’s Group chief executive officer. “Our objective with each enhancement is the pursuit of our mission – to eliminate advanced-stage breast cancer and save more families from cancer.”
With this approval, Volpara marks its fifth clearance since launching Volpara Imaging Software in 2010. It is a key science algorithm that supports the Volpara Breast Health Platform, a product suite designed to improve early breast cancer detection through augmented mammography quality and workflow, volumetric breast density assessment, and personalized breast care.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.